KR101412786B1 - 신규 피롤로[3,2-ｄ]피리미딘-4-온 유도체 및 이의 치료용도 - Google Patents

신규 피롤로[3,2-ｄ]피리미딘-4-온 유도체 및 이의 치료용도 Download PDF

Info

Publication number
KR101412786B1
KR101412786B1 KR1020077012654A KR20077012654A KR101412786B1 KR 101412786 B1 KR101412786 B1 KR 101412786B1 KR 1020077012654 A KR1020077012654 A KR 1020077012654A KR 20077012654 A KR20077012654 A KR 20077012654A KR 101412786 B1 KR101412786 B1 KR 101412786B1
Authority
KR
South Korea
Prior art keywords
mmol
pyrrolo
delete delete
thioxo
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077012654A
Other languages
English (en)
Korean (ko)
Other versions
KR20070090178A (ko
Inventor
안더스 뵈게빅
이본느 로-알프레드손
도날드 피본카
안나-카린 티덴
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36578191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101412786(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0402972A external-priority patent/SE0402972D0/sv
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20070090178A publication Critical patent/KR20070090178A/ko
Application granted granted Critical
Publication of KR101412786B1 publication Critical patent/KR101412786B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077012654A 2004-12-06 2005-12-05 신규 피롤로[3,2-ｄ]피리미딘-4-온 유도체 및 이의 치료용도 Expired - Lifetime KR101412786B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0402972A SE0402972D0 (sv) 2004-12-06 2004-12-06 Novel compounds
SE0402972-4 2004-12-06
SE0501093-9 2005-05-13
SE0501093 2005-05-13
PCT/SE2005/001835 WO2006062465A1 (en) 2004-12-06 2005-12-05 Novel pyrrolo [3, 2-d] pyrimidin-4-one derivatives and their use in therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137005332A Division KR101412939B1 (ko) 2004-12-06 2005-12-05 신규 피롤로[3,2-ｄ]피리미딘-4-온 유도체 및 이의 치료 용도

Publications (2)

Publication Number Publication Date
KR20070090178A KR20070090178A (ko) 2007-09-05
KR101412786B1 true KR101412786B1 (ko) 2014-06-30

Family

ID=36578191

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020077012654A Expired - Lifetime KR101412786B1 (ko) 2004-12-06 2005-12-05 신규 피롤로[3,2-ｄ]피리미딘-4-온 유도체 및 이의 치료용도
KR1020137033109A Expired - Lifetime KR101557715B1 (ko) 2004-12-06 2005-12-05 신규 피롤로[3,2-ｄ]피리미딘-4-온 유도체 및 이의 치료 용도
KR1020137005332A Expired - Lifetime KR101412939B1 (ko) 2004-12-06 2005-12-05 신규 피롤로[3,2-ｄ]피리미딘-4-온 유도체 및 이의 치료 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020137033109A Expired - Lifetime KR101557715B1 (ko) 2004-12-06 2005-12-05 신규 피롤로[3,2-ｄ]피리미딘-4-온 유도체 및 이의 치료 용도
KR1020137005332A Expired - Lifetime KR101412939B1 (ko) 2004-12-06 2005-12-05 신규 피롤로[3,2-ｄ]피리미딘-4-온 유도체 및 이의 치료 용도

Country Status (29)

Country Link
US (3) US7829707B2 (enExample)
EP (1) EP1824855B1 (enExample)
JP (1) JP5028270B2 (enExample)
KR (3) KR101412786B1 (enExample)
CN (1) CN101072778B (enExample)
AR (1) AR051698A1 (enExample)
AU (1) AU2005312388B2 (enExample)
BR (1) BRPI0518846B1 (enExample)
CA (1) CA2591314C (enExample)
CY (1) CY1113209T1 (enExample)
DK (1) DK1824855T3 (enExample)
ES (1) ES2390888T3 (enExample)
HR (1) HRP20120781T1 (enExample)
IL (1) IL183182A (enExample)
ME (1) ME01486B (enExample)
MX (1) MX2007006497A (enExample)
MY (1) MY140748A (enExample)
NO (1) NO20072399L (enExample)
NZ (1) NZ555046A (enExample)
PL (1) PL1824855T3 (enExample)
PT (1) PT1824855E (enExample)
RS (1) RS52490B (enExample)
RU (2) RU2409578C2 (enExample)
SA (1) SA05260385B1 (enExample)
SI (1) SI1824855T1 (enExample)
TW (1) TWI365189B (enExample)
UA (1) UA89968C2 (enExample)
UY (1) UY29246A1 (enExample)
WO (1) WO2006062465A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
CA2643235C (en) * 2006-02-21 2014-06-17 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
WO2007120097A1 (en) * 2006-04-13 2007-10-25 Astrazeneca Ab Thioxanthine derivatives and their use as inhibitors of mpo
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
JP5201063B2 (ja) * 2008-04-15 2013-06-05 信越化学工業株式会社 付加硬化型シリコーン組成物及びその硬化物
EP2411393B1 (en) 2009-03-23 2014-01-22 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as trpa1 modulators
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
JP5731718B2 (ja) 2011-11-11 2015-06-10 ファイザー・インク ２−チオピリミジノン
WO2013150115A1 (en) * 2012-04-05 2013-10-10 Basf Se N- substituted hetero - bicyclic compounds and derivatives for combating animal pests
PH12019502809B1 (en) 2012-06-13 2024-04-24 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
PL2864323T3 (pl) 2012-06-15 2017-09-29 Janssen Sciences Ireland Uc Pochodne 1,3-dihydro-2h-benzoimidazol-2-onu podstawione heterocyklami jako środki przeciwwirusowe przeciwko wirusowi syncytium nabłonka oddechowego
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US9920075B2 (en) 2014-09-11 2018-03-20 Bristol-Myers Squibb Company Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
JP2018515480A (ja) 2015-05-05 2018-06-14 ファイザー・インク ２−チオピリミジノン
US10407422B2 (en) 2015-09-03 2019-09-10 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase
US10214527B2 (en) * 2015-09-03 2019-02-26 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase
WO2017160632A1 (en) * 2016-03-14 2017-09-21 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MY200803A (en) 2017-07-17 2024-01-16 Astrazeneca Ab Mpo inhibitors for use in medicine
WO2019078871A1 (en) 2017-10-19 2019-04-25 Texas State University PHOTOACTIVABLE PRODRANT AGAINST CANCER
CN112867716B (zh) 2018-05-04 2024-09-13 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
JP7568512B2 (ja) 2018-05-04 2024-10-16 インサイト・コーポレイション Ｆｇｆｒ阻害剤の塩
WO2020021300A1 (en) 2018-07-24 2020-01-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of myeloperoxidase (mpo) inhibitors for the treatment of chemoresistant acute myeloid leukemia (aml)
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021013942A1 (en) 2019-07-24 2021-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of myeloperoxidase inhibitors for the treatment of cardiovascular diseases in patients suffering from myeloproliferative neoplasms
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020363903A1 (en) * 2019-10-10 2022-03-24 Biohaven Therapeutics Ltd. Prodrugs of myeloperoxidase inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2021230370A1 (en) * 2020-03-05 2022-10-20 Biohaven Therapeutics Ltd. Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor
US20230192700A1 (en) 2020-03-06 2023-06-22 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12
EP4146219A4 (en) * 2020-05-06 2024-05-22 Biohaven Therapeutics Ltd. PROCESS FOR PREPARING VERDIPERSTAT
EP4165034A1 (en) 2020-06-11 2023-04-19 Janssen Sciences Ireland Unlimited Company Hemi (l)-tartrate forms of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1h-indol-2 yl} methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one and pharmaceutical compositions comprising the same
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
JP2024522188A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
AU2023326686A1 (en) 2022-08-18 2025-04-03 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2024120457A1 (zh) * 2022-12-09 2024-06-13 深圳信立泰药业股份有限公司 一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途
WO2025107036A1 (en) * 2023-11-23 2025-05-30 Syntara Limited Dual inhibitors of amine oxidases and peroxidases, and uses thereof
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040091A1 (en) 1998-02-06 1999-08-12 Amgen Inc. Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists
WO2000059449A2 (en) 1999-04-02 2000-10-12 Euro-Celtique S.A. Purine derivatives having phosphodiesterase iv inhibition activity
WO2003000694A1 (en) 2001-06-22 2003-01-03 Almirall Prodesfarma S.A. 6-phenyldihydropyrrolopyrimidinedione derivatives
WO2003089430A1 (en) 2002-04-19 2003-10-30 Astrazeneca Ab Thioxanthine derivatives as myeloperoxidase inhibitors

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135753A (en) * 1961-05-10 1964-06-02 Burroughs Wellcome Co Alkylthiopurines and method
US3652579A (en) 1969-06-26 1972-03-28 Hoffmann La Roche 1-methyl-2-substituted 5-nitroimidazoles
SE7810947L (sv) 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
US4710503A (en) 1985-02-07 1987-12-01 Euroceltique S.A. 6-thioxanthine derivatives
WO1989006125A1 (en) 1987-12-31 1989-07-13 Smithkline Beckman Corporation 4-aralkyl-5-substituted-1,2,4-triazole-5-thiols
DK440989A (da) 1988-09-12 1990-03-13 Smithkline Beecham Corp Dopamin-beta-hydroxylase inhibitorer
JPH02160235A (ja) 1988-12-13 1990-06-20 Konica Corp ハロゲン化銀カラー写真画像の形成方法
EP0430300A3 (en) 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
US5100906A (en) 1990-04-19 1992-03-31 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3h-1,2,4-triazole-3-thiones useful as memory enhancers
FR2665636B1 (fr) * 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
US6046019A (en) * 1991-07-09 2000-04-04 Goumeniouk; Alexander P. Diagnostic kits and methods for making granulocyte cell counts
US5281209A (en) 1992-06-30 1994-01-25 The Procter & Gamble Company Absorbent article having tucked flaps
KR950701335A (ko) 1992-04-21 1995-03-23 존 에어. 몽고메리 7-이치환된 메틸-4-옥소-3H,5H-피롤로[3,2-d]-피리미딘 및 이를 함유하는 약제 조성물
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
PL314605A1 (en) * 1993-11-26 1996-09-16 Pfizer Isoxazolin compounds as anti-inflammatory agents
US5489598A (en) * 1994-06-08 1996-02-06 Warner-Lambert Company Cytoprotection utilizing aryltriazol-3-thiones
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
WO1996018400A1 (en) 1994-12-13 1996-06-20 Euro-Celtique, S.A. Trisubstituted thioxanthines
US6066641A (en) * 1994-12-13 2000-05-23 Euro-Celtique S.A. Aryl thioxanthines
US5756511A (en) * 1995-04-03 1998-05-26 Cell Therapeutics, Inc. Method for treating symptoms of a neurodegenerative condition
US6294541B1 (en) * 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
GB9626643D0 (en) 1996-12-21 1997-02-12 Astra Pharma Prod Compounds
US5976823A (en) * 1997-03-19 1999-11-02 Integrated Biomedical Technology, Inc. Low range total available chlorine test strip
EP1016407B1 (en) 1997-09-05 2006-05-10 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for treating brain ischemia
WO1999014204A1 (en) 1997-09-16 1999-03-25 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
US6319928B1 (en) * 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
DZ3019A1 (fr) 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
GB2362101A (en) 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
FR2811989A1 (fr) 2000-07-18 2002-01-25 Sanofi Synthelabo Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique
WO2002008237A2 (en) 2000-07-21 2002-01-31 Lyles Mark B Materials and methods for binding nucleic acids to surfaces
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100620D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
FR2819723B1 (fr) * 2001-01-23 2006-11-17 Arnaud Mainnemare Composition halogene, son procede de preparation et ses utilisations
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
SE0103766D0 (sv) * 2001-11-09 2001-11-09 Astrazeneca Ab Novel assay
IL158462A0 (en) 2001-05-08 2004-05-12 Astrazeneca Ab An assay for detecting inhibitors of the enzyme myeloperoxidase
CN101822676A (zh) 2002-01-28 2010-09-08 协和发酵麒麟株式会社 治疗运动疾病患者的方法
ES2208063B1 (es) * 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
SE0301232D0 (sv) * 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
US7449473B2 (en) 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists
PL1781657T3 (pl) 2004-02-14 2013-08-30 Glaxosmithkline Ip Dev Ltd Leki o aktywności wobec receptora HM74A
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
SE0402591D0 (sv) 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
US20090124640A1 (en) 2006-06-05 2009-05-14 Astrazeneca Ab Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
AR066936A1 (es) 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040091A1 (en) 1998-02-06 1999-08-12 Amgen Inc. Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists
WO2000059449A2 (en) 1999-04-02 2000-10-12 Euro-Celtique S.A. Purine derivatives having phosphodiesterase iv inhibition activity
WO2003000694A1 (en) 2001-06-22 2003-01-03 Almirall Prodesfarma S.A. 6-phenyldihydropyrrolopyrimidinedione derivatives
WO2003089430A1 (en) 2002-04-19 2003-10-30 Astrazeneca Ab Thioxanthine derivatives as myeloperoxidase inhibitors

Also Published As

Publication number Publication date
CN101072778A (zh) 2007-11-14
US20080221136A1 (en) 2008-09-11
HK1110859A1 (en) 2008-07-25
DK1824855T3 (da) 2012-10-15
HRP20120781T1 (hr) 2012-10-31
RU2409578C2 (ru) 2011-01-20
NZ555046A (en) 2010-08-27
CY1113209T1 (el) 2016-04-13
WO2006062465A1 (en) 2006-06-15
IL183182A (en) 2012-02-29
RS52490B (sr) 2013-02-28
AU2005312388A1 (en) 2006-06-15
JP5028270B2 (ja) 2012-09-19
US9580429B2 (en) 2017-02-28
AR051698A1 (es) 2007-01-31
RU2007119307A (ru) 2009-01-20
KR20130037236A (ko) 2013-04-15
PT1824855E (pt) 2012-10-09
US8859568B2 (en) 2014-10-14
TW200626601A (en) 2006-08-01
ES2390888T3 (es) 2012-11-19
RU2010139806A (ru) 2012-04-10
UY29246A1 (es) 2006-08-31
KR101557715B1 (ko) 2015-10-06
US20110059996A1 (en) 2011-03-10
NO20072399L (no) 2007-08-24
BRPI0518846B1 (pt) 2022-04-05
CA2591314C (en) 2011-06-21
MY140748A (en) 2010-01-15
SA05260385B1 (ar) 2009-02-25
CA2591314A1 (en) 2006-06-15
US7829707B2 (en) 2010-11-09
EP1824855A4 (en) 2010-12-08
CN101072778B (zh) 2011-06-15
EP1824855B1 (en) 2012-08-08
JP2008522968A (ja) 2008-07-03
PL1824855T3 (pl) 2012-11-30
AU2005312388B2 (en) 2009-10-29
KR20070090178A (ko) 2007-09-05
KR20140010177A (ko) 2014-01-23
IL183182A0 (en) 2007-09-20
ME01486B (me) 2014-04-20
US20150099769A1 (en) 2015-04-09
RU2577858C2 (ru) 2016-03-20
MX2007006497A (es) 2007-06-22
UA89968C2 (uk) 2010-03-25
BRPI0518846A2 (pt) 2008-12-09
EP1824855A1 (en) 2007-08-29
KR101412939B1 (ko) 2014-06-26
TWI365189B (en) 2012-06-01
SI1824855T1 (sl) 2012-11-30

Similar Documents

Publication Publication Date Title
KR101412786B1 (ko) 신규 피롤로[3,2-ｄ]피리미딘-4-온 유도체 및 이의 치료용도
EP2010535B1 (en) Thioxanthine derivatives and their use as inhibitors of mpo
RU2435772C2 (ru) Производные 2-тиоксантина, действующие в качестве ингибиторов мро
JP2009533426A (ja) チオキサンチン誘導体およびそれらのｍｐｏ阻害剤としての用途
HK1110859B (en) Novel pyrrolo [3, 2-d] pyrimidin-4-one derivatives and their use in therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070605

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20101203

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120830

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20130228

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130731

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20140321

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20140620

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20140620

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20170522

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20170522

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20180516

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20180516

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20190515

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20190515

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20210517

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20220517

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20230518

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20240522

Start annual number: 11

End annual number: 11